Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

629
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
629
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers.

JCO precision oncology·2026
Same author

Advancing the Oncology Data Paradigm: Multisite Expansion of Structured Cancer Data Capture at the Point of Care.

JCO oncology practice·2026
Same author

Small Cell and Large Cell Neuroendocrine Carcinoma of the Colon and Rectum: Population-Based Analysis of Incidence, Survival, and Site-Specific Outcomes.

Cancers·2026
Same author

Circulating Biomarkers in Localized Anal Squamous Cell Carcinoma Across Treatment Timepoints: A Systematic Review.

Cancers·2026
Same author

Multi-institutional care is associated with improved survival in biliary tract cancer.

Journal of gastrointestinal oncology·2026
Same author

Characterization of Patients with Unresectable Hepatocellular Carcinoma in REFLECT Who Achieved Tumor Response or Alpha-Fetoprotein Response When Treated with Lenvatinib.

Liver cancer·2026

Related Experiment Video

Updated: Aug 18, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.0K

Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations.

Michael H Storandt1, Amit Mahipal2, Sri Harsha Tella2

  • 1Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

Journal of Hepatocellular Carcinoma
|December 6, 2022
PubMed
Summary

New systemic therapies have transformed first-line treatment for advanced hepatocellular carcinoma (HCC). Combinations like atezolizumab/bevacizumab and durvalumab/tremelimumab show significant survival benefits over sorafenib.

Keywords:
advanced hepatocellular carcinomahepatocellular carcinoma

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.3K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

555

Related Experiment Videos

Last Updated: Aug 18, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.0K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.3K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

555

Area of Science:

  • Hepatocellular Carcinoma (HCC) Treatment
  • Oncology
  • Medical Therapeutics

Background:

  • Hepatocellular carcinoma (HCC) is a major global cause of cancer mortality.
  • Advanced, unresectable HCC historically had limited systemic treatment options, primarily sorafenib.
  • Recent years have seen significant advancements and new drug approvals for HCC.

Purpose of the Study:

  • To review current first-line systemic treatment options for advanced hepatocellular carcinoma (HCC).
  • To address key questions regarding the optimization of HCC treatment strategies.
  • To highlight recent changes in the HCC treatment landscape.

Main Methods:

  • Review of recent clinical trials and regulatory approvals.
  • Analysis of efficacy data for novel systemic therapies in first-line HCC treatment.
  • Focus on combination therapies and targeted agents.

Main Results:

  • Atezolizumab plus bevacizumab demonstrated superior response rates, progression-free survival, and overall survival compared to sorafenib.
  • Durvalumab plus tremelimumab showed improved overall survival versus sorafenib; durvalumab monotherapy was noninferior.
  • Several targeted therapies (lenvatinib, cabozantinib, ramucirumab, regorafenib) are now approved for advanced HCC.

Conclusions:

  • The treatment paradigm for first-line advanced HCC has dramatically shifted with new immunotherapy and targeted drug approvals.
  • Combination therapies and novel agents offer improved outcomes and alternatives to traditional treatments.
  • Ongoing research aims to further optimize these systemic treatments for better patient survival.